CD133 is a particularly attractive candidate since elevated expression of this cancer stem cell marker and CD44 has been detected in prostate carcinomas, even though the clinical significance of this observation needs to be further elucidated (Kalantari et al., 2017a). This evidence concerns the gene PROM1 and cancer.